aibioEvommune drops EVO756 in atopic dermatitis after phase 2b misses all endpoints
Tickers EVMN
The 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans.
Key facts
- Company
- Evommune, Inc. (NYSE: EVMN)
- News type
- Distress
- Primary source
- EVMN 8-K
Evommune, Inc. (NYSE: EVMN) said on September 8, 2026 that EVO756, its oral MRGPRX2 antagonist, did not work in a Phase 2b trial in moderate-to-severe atopic dermatitis (AD). The press release describes a randomized, double-blind, placebo-controlled, dose-ranging study that enrolled 121 adults over 12 weeks, with follow-up through week 14. The trial missed its primary endpoint, the percent change from baseline in Eczema Area and Severity Index (EASI) score at week 12, and its secondary endpoints, at every dose studied. The company no longer plans to advance EVO756 in AD.
A program built on a small study
The AD trial followed earlier data from a small study. In its November 2025 prospectus, the company cited a Phase 2 trial in chronic inducible urticaria, in people with symptomatic dermographism, as support for starting the AD program. That study had 27 observed patients. Of them, 70% (n=19) improved at four weeks and 30% (n=8) reached a complete response. The company argued that neurogenic inflammation plays a crucial role in both conditions. The 121-patient AD trial did not show the effect the company had cited.
The Phase 1 study in 132 healthy volunteers found EVO756 well tolerated, but it was designed to test safety and dosing, not whether the drug works in patients. The release says the drug was generally well tolerated in the AD trial, with a safety profile consistent with prior studies. It gives no adverse-event counts for that trial. Chief executive Luis Peña said the trial "did not deliver the outcome we and the AD community were hoping for."
What the company keeps and moves forward
Evommune will continue to evaluate EVO756 in migraine prophylaxis. Its second candidate, EVO301, is a long-acting injectable fusion protein that targets IL-18 activity. The release says EVO301 produced positive Phase 2a proof-of-concept data and is now the lead atopic dermatitis program. A Phase 2b trial is planned for mid-2027. The release gives no efficacy numbers for the Phase 2a study, so the lead program's evidence rests on a company description.
The money behind the timeline
The 2025 annual report, filed March 5, 2026, showed a net loss of $68.9 million for 2025, against $66.8 million in 2024. Research and development expense was $74.0 million in 2025. Cash used in operations rose to $76.4 million from $58.2 million, and revenue was $13.0 million in 2025 and $7.0 million in 2024.
The quarterly report filed August 6, 2026 put cash and cash equivalents at $60.0 million on June 30, 2026, plus $140.8 million in short-term investments. At the end of 2025 the company held $44.1 million in cash and equivalents and $105.1 million in short-term investments. Evommune now expects cash, cash equivalents and investments to fund operations into 2029.
That runway depends on the revised plans. The company says it rests on current business plans, including the revised development plans in the release. Those plans drop the AD work, continue the migraine program and move EVO301 toward a mid-2027 trial. The release gives no cost for those programs. In 2025 cash used in operations exceeded the net loss, and the release does not say how much of the runway depends on stopping the AD work.
What to watch
The next dated milestone in the release is the EVO301 Phase 2b, planned for mid-2027. The release gives no start date for the migraine trial. The next quarterly report will show how quickly cash is falling against the 2029 forecast.